Kytril

Granisetron, the active ingredient in Kytril, is a 5-HT3 receptor antagonist presented as a injection solution for intravenous use. It treats and prevents chemotherapy‑induced nausea and vomiting as well as postoperative nausea and vomiting in adult patients. It is employed in both adult and pediatric oncology settings where appropriate.

GNH USA supplies Kytril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with distribution networks across Europe, Asia and other regions, and complies with EU regulatory standards for quality and safety.

Granisetron is a 5‑HT3 receptor antagonist used to control nausea and vomiting associated with chemotherapy and surgery.

Chemotherapy‑induced nausea and vomiting: Prevents and treats acute and delayed episodes in patients receiving emetogenic chemotherapy. Postoperative nausea and vomiting: Reduces incidence of nausea and vomiting after surgical procedures. Radiation therapy‑induced nausea and vomiting: Provides prophylaxis for patients undergoing radiotherapy.

Granisetron may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate head pain. - Constipation: reduced bowel movements. - Dizziness: sensation of light‑headedness. - Injection site pain: discomfort at the IV site.

Serious or Rare Side Effects: - QT interval prolongation: potential cardiac rhythm disturbance. - Anaphylaxis: severe allergic reaction with airway compromise. - Severe hypotension: marked drop in blood pressure. - Serotonin syndrome: rare condition with agitation, hyperthermia, and neuromuscular abnormalities.

When using Kytril, consider the following safety measures.

Assess cardiac history: evaluate baseline ECG for QT prolongation risk. Avoid concomitant drugs that prolong QT interval: monitor when used with other QT‑prolonging agents. Monitor for allergic reactions: discontinue if signs of hypersensitivity appear. Use with caution in hepatic impairment: adjust if liver function is compromised. Pregnancy and breastfeeding: safety not established; weigh benefits versus risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Granisetron can interact with other medicines; review the following.

Major Interactions (Avoid): - Other QT‑prolonging drugs (e.g., quinidine, haloperidol): increased risk of cardiac arrhythmia. - CYP3A4 inhibitors (e.g., ketoconazole): may raise granisetron plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce granisetron efficacy.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may enhance constipation. - Other antiemetics (e.g., ondansetron): additive serotonergic effects. - Anesthetic agents (e.g., propofol): may potentiate hypotension.